Navigation Links
Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference

BEDMINSTER, N.J., Nov. 11, 2010 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that Jerry Wisler, President and Chief Executive Officer, will present at the Lazard Capital Markets 7th Annual Healthcare Conference at the St. Regis hotel in New York City on November 17, 2010 at  1:15pm Eastern time.

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia.  Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.  The lead product candidate is Epanova, an Omega 3 fatty acid compound preparing to enter Phase III clinical development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (greater than or equal to 500 mg/dL).  Future planned clinical trials for Epanova include patients with high triglycerides (greater than or equal to 200 mg/dL and less than or equal to 500 mg/dL) currently on statin therapy.  Omthera holds worldwide rights to Epanova.   For more information, please visit ContactRx Communications Group, LLCEric GoldmanVice President, Public

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
(Date:10/13/2015)... Oct. 13, 2015 Attracting mid- to large-sized medical ... to growing Baltimore into a major ... by the Maryland Technology Enterprise Institute (Mtech) . ... pieces in place to support innovation hubs and a thriving ... Mtech Baltimore. "This study is important because we believe ...
(Date:10/13/2015)... , Oct. 13, 2015  Graduate students ... care and medical research, will soon have the ... patient care – the drug discovery and development ... ) has collaborated with 10 leaders from academic ... "Making Medicines: The Process of Drug Development."  Lilly ...
(Date:10/13/2015)... SAN FRANCISCO , October 13, 2015 ... expected to reach USD 26.8 billion by 2022, according ... Anesthesia and respiratory devices, owing to their capability to ... expected to witness a substantial growth. --> ... reach USD 26.8 billion by 2022, according to a ...
Breaking Medicine Technology:
(Date:10/13/2015)... Boulder, Colorado (PRWEB) , ... October 13, 2015 ... ... launched the first high-tech foam roller with 11 hours of vibrating power. Tested ... to reduce recovery time and increase athletic performance. , Mark's background in sporting ...
(Date:10/13/2015)... , ... October 13, 2015 , ... The American Institutes ... college campus health staff caring for students who have experienced sexual assault and other ... the White House during the Violence Against Women Act's 21st anniversary. ...
(Date:10/13/2015)... M.A. (PRWEB) , ... October 13, 2015 , ... Sir ... service to the local Boston chapter of Ronald McDonald House Charities® (RMHC®). This ... that has supported Sir Grout of Greater Boston since its inception. , “We believe ...
(Date:10/13/2015)... ... ... "My friend's son suffers from eczema, and he had a horrible habit ... Platteville, Colo. "I came up with this kit as a way to prevent children ... child from rubbing or scratching his or her face. This protects sensitive skin from ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... anesthesia and pain management services, today announced its partnership with WPC Healthcare ... data from disparate systems and organizes the data into an aggregated data repository ...
Breaking Medicine News(10 mins):